Salehiya Trading Company Pharmaceutical Import Profile — Saudi Arabia (DGFT 2022–2026)

Name: Salehiya Trading Company Pharmaceutical Import Records from India — 3 Products, $3.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Salehiya Trading Company — Pharmaceutical Importer Profile (2026) | 3 Products, $3.3M Trade | TransData Nexus

Salehiya Trading Company

Pharmaceutical Importer · Saudi Arabia · Advanced Antibiotics Focus · $3.3M Total Trade · DGFT Verified

Salehiya Trading Company is a pharmaceutical importer based in Saudi Arabia with a total trade value of $3.3M across 3 products in 3 therapeutic categories. Based on 119 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Salehiya Trading Company sources from 3 verified Indian suppliers, with Glenmark Pharmaceuticals Limited accounting for 66.8% of imports.

Salehiya Trading Company — Import Portfolio & Supplier Network

Salehiya Trading Company import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Salehiya Trading Company?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Glenmark Pharmaceuticals Limited	$5.6M	182	66.8%
Venus Remedies Limited	$2.7M	399	32.6%
Cipla Limited

What Formulations Does Salehiya Trading Company Import?

Formulation	Value	Ships
Meropenem 1.0 GM powder for solution	$619.7K	32
Combiwave 125/120mdi	$491.2K	13
Combiwave 250/ 120 mdi sa batch no mfg	$400.0K	8
Flusort ns 50 MCG 120md	$338.5K	14
Flusort ns 50 MCG 120md	$303.7K	10
Combiwave 125/120mdi	$300.0K	6
Combiwave 50/120mdi sa batch no mfg dt	$200.0K	4
Combiwave 50/120mdi	$187.3K	4
Tacroz forte ointment 0.1% 10 g	$182.0K	4
Combiwave 250 120 mdi sa n c v	$150.0K	3
Malaust (atov+prog) TAB	$146.7K	3
Tacroz ointment 0.03% 10 GM	$132.4K	4
Malaust (atov+prog) TAB 1x12s	$128.3K	3
Meropenem 500 MG powder for solution	$123.8K	8
Kozamod 5% 0.25 g x 12 sachets	$110.2K	3

Salehiya Trading Company imports 341 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Meropenem	Advanced Antibiotics	$3.2M	64	1.4%	8
2	Vincristine	Oncology	$73.3K	36	3.6%	3
3	Dacarbazine	Advanced Oncology	$52.4K	19	3.7%	5

Salehiya Trading Company imports 3 pharmaceutical products across 3 categories into Saudi Arabia totaling $3.3M.

Salehiya Trading Company — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Salehiya Trading Company, established in 1964, is a prominent Saudi Arabian entity specializing in the distribution of pharmaceuticals, medical equipment, and patient and consumer care products. Headquartered in Riyadh, the company has expanded its operations to include branches in Jeddah, Dammam, Khamis Mushait, Qassim, and Medina Al-Munawarah, ensuring comprehensive coverage across the Kingdom.

As a private joint-stock company, Salehiya Trading Company plays a pivotal role in Saudi Arabia's pharmaceutical supply chain, acting as a primary wholesaler and distributor. The company collaborates with international partners to import and distribute a diverse range of pharmaceutical products, medical devices, and consumer health items, thereby enhancing the healthcare experience within the Kingdom.

2Distribution Network

Salehiya Trading Company operates an extensive distribution network with its headquarters in Riyadh and additional branches in Jeddah, Dammam, Khamis Mushait, Qassim, and Medina Al-Munawarah. This strategic placement enables the company to effectively serve clients across Saudi Arabia. The company has been certified by SGS for compliance with World Health Organization (WHO) Good Distribution Practices (GDP), establishing it as a leader in the warehousing and transportation of pharmaceutical products within the Kingdom.

3Industry Role

In Saudi Arabia's pharmaceutical supply chain, Salehiya Trading Company serves as a primary wholesaler and distributor. By importing and distributing a diverse range of pharmaceutical products, medical devices, and consumer health items, the company plays a crucial role in enhancing the healthcare experience within the Kingdom.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Salehiya Trading Company

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Salehiya Trading Company's sourcing strategy exhibits a high degree of concentration, with a total import value of $3.3 million USD from India across 119 shipments. The top five imported products—Meropenem, Vincristine, and Dacarbazine—account for 100% of the company's imports from India. This indicates a strategic focus on specific therapeutic areas, particularly advanced antibiotics and oncology treatments.

The company's reliance on a limited number of suppliers—GLENMARK PHARMACEUTICALS LIMITED, VENUS REMEDIES LIMITED, and CIPLA LIMITED—suggests a stable and possibly long-term relationship with these partners. However, this concentration also presents potential risks, such as supply chain disruptions or pricing volatility. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

Salehiya Trading Company's supply chain resilience is closely tied to its partnerships with Indian suppliers. The company's focus on a limited number of suppliers for its top imported products indicates a stable relationship, which is beneficial for consistent product availability. However, this concentration also exposes the company to potential risks, such as supply chain disruptions or pricing volatility. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

Importing Pharmaceuticals into Saudi Arabia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Saudi Arabia

1Regulatory Authority & Framework

The Saudi Food and Drug Authority (SFDA) is the primary regulatory body overseeing the pharmaceutical sector in Saudi Arabia. The SFDA is responsible for regulating the import, registration, and distribution of pharmaceutical products, ensuring they meet the Kingdom's health and safety standards. The Law of Pharmaceutical Establishments and Products (2023), issued under Royal Decree No. M/108, provides the legal framework governing medicinal products, herbal preparations, and pharmaceutical operations in the Kingdom.

2Import Licensing & GMP

Importing pharmaceutical products into Saudi Arabia requires compliance with specific licensing and certification requirements. A Certificate of Free Sale from the exporting country's Department of Health and Human Services is mandatory for all pharmaceutical shipments. Additionally, the Saudi Food and Drug Authority (SFDA) mandates that imported pharmaceutical products be registered and approved before entering the Saudi market. The SFDA also recognizes Good Manufacturing Practice (GMP) certifications from reputable international bodies, such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S), ensuring that imported products meet high-quality standards.

Quality & Labeling

Salehiya Trading Company — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Salehiya Trading Company's product strategy focuses on advanced antibiotics and oncology treatments, with Meropenem, Vincristine, and Dacarbazine being the top imported products. This focus aligns with the growing demand for specialized healthcare solutions in Saudi Arabia, driven by an aging population and increasing prevalence of chronic diseases. By concentrating on these therapeutic areas, Salehiya aims to address critical healthcare needs and strengthen its position in the market.

2Sourcing Profile

Salehiya Trading Company's sourcing strategy emphasizes importing finished pharmaceutical formulations from India, particularly in the categories of advanced antibiotics and oncology treatments. This approach leverages India's established pharmaceutical manufacturing capabilities and cost advantages. The company's focus on a limited number of suppliers suggests a strategic choice to maintain quality control and supplier reliability. However, this concentration also exposes the company to potential risks, such as supply chain disruptions or pricing volatility.

3Market Positioning

Salehiya Trading Company's focus on advanced antibiotics and oncology treatments positions it to serve the specialized segments of the Saudi Arabian pharmaceutical market. By importing and distributing these high-demand products, the company caters to hospitals, specialized clinics, and healthcare providers requiring advanced therapeutic solutions. This strategic positioning allows Salehiya to address critical healthcare needs and strengthen its presence in the market.

Seller's Guide — How to Become a Supplier to Salehiya Trading Company

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

For new Indian suppliers, there is a realistic opportunity to partner with Salehiya Trading Company, given the company's focus on advanced antibiotics and oncology treatments. Suppliers can explore avenues to diversify Salehiya's product portfolio within these therapeutic areas. However, potential suppliers should be aware of the risks associated with high supplier concentration and consider strategies to mitigate these risks.

2Requirements & Qualifications

Indian exporters seeking to supply Salehiya Trading Company and the Saudi Arabian market must ensure compliance with the Saudi Food and Drug Authority's (SFDA) regulations. This includes obtaining a Certificate of Free Sale from the exporting country's Department of Health and Human Services and ensuring that products meet SFDA's quality standards, including Good Manufacturing Practice (GMP) certifications from recognized international bodies. Additionally, products must be registered with the SFDA before importation.

3How to Approach

Frequently Asked Questions — Salehiya Trading Company

What products does Salehiya Trading Company import from India?

Salehiya Trading Company imports 3 pharmaceutical products across 3 categories. Top imports: Meropenem ($3.2M), Vincristine ($73.3K), Dacarbazine ($52.4K).

Who supplies pharmaceuticals to Salehiya Trading Company from India?

Salehiya Trading Company sources from 3 verified Indian suppliers. The primary supplier is Glenmark Pharmaceuticals Limited (66.8% of imports, $5.6M).

What is Salehiya Trading Company's total pharmaceutical import value?

Salehiya Trading Company's total pharmaceutical import value from India is $3.3M, based on 119 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Salehiya Trading Company focus on?

Salehiya Trading Company imports across 3 categories. The largest: Advanced Antibiotics (96.2%), Oncology (2.2%), Advanced Oncology (1.6%).

Get Full Salehiya Trading Company Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.